iFuse Bedrock Granite®
-
Spine
SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™
The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in…
Read More » -
Spine
SI-BONE Expands Portfolio with the Launch of New Offering for the iFuse Bedrock Granite Implant System and Completes Inaugural Surgical Procedures
SANTA CLARA, Calif., May 07, 2024 (GLOBE NEWSWIRE) — SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated…
Read More » -
Regulatory
SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application
SANTA CLARA, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) — SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated…
Read More » -
Spine
SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera® 5.5/6.0 System Rods
SANTA CLARA, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company focused…
Read More » -
Regulatory
SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite® Implant System
New Indications Include Use with a Broad Class of Commercially Available Rods SANTA CLARA, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE)…
Read More » -
Regulatory
SI-BONE, Inc. Receives FDA 510(k) Clearance for iFuse Bedrock Granite, a Breakthrough Pelvic Fixation and Fusion Technology
SANTA CLARA, Calif., May 31, 2022 (GLOBE NEWSWIRE) — SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to…
Read More »